SCHEDULE: Saba Capital Conditionally Withdraws BlackRock ESG Board Nominee

Saba Capital Management has conditionally withdrawn its proposed nomination of Lawrence Epstein for the BlackRock ESG Capital Allocation Term Trust board, contingent on board structure.

Summary

• Saba Capital Management, L.P., Saba Capital Management GP, LLC, and Boaz R. Weinstein (Reporting Persons) jointly filed Amendment No. 31 to Schedule 13D.
• The Reporting Persons beneficially own 22,451,311 Common Shares of BlackRock ESG Capital Allocation Term Trust, representing 22.57% of the class.
• This percentage is calculated based on 99,468,307 shares of common stock outstanding as of December 31, 2025, as disclosed in the company's N-CSR filed on March 5, 2026.
• Saba Capital Master Fund, Ltd. conditionally agreed to withdraw its proposed nomination of Lawrence Epstein as a Class I Nominee for the Issuer's 2026 annual meeting of shareholders.
• The withdrawal is subject to and conditioned upon there being no more than nine seats up for election at the Issuer's 2026 annual meeting and the Issuer not maneuvering its Board in a way that disadvantages or mitigates Saba's other validly nominated slate.
• Approximately $333,748,145 was paid to acquire the reported Common Shares.
• Saba Capital sold 109,941 shares at $14.52 on March 12, 2026, and 33,774 shares at $14.16 on March 13, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development for the Issuer as it conditionally reduces immediate proxy fight pressure, but the conditions maintain some uncertainty and leverage for the activist.

Positives

• The conditional withdrawal of a board nominee could potentially reduce the immediate threat of a proxy contest for BlackRock ESG Capital Allocation Term Trust, provided the specified conditions are met.

Negatives

• The withdrawal of the nominee is conditional, meaning the proxy contest risk is not fully eliminated and could be reinstated if the Issuer's board structure changes or other nominees are challenged.
• Saba Capital sold a total of 143,715 shares between March 12-13, 2026.

Risks

• The Issuer's potential actions, such as expanding its Board, shuffling Board classes, or claiming any of Saba's other nominees are invalid, could nullify the withdrawal of Lawrence Epstein's nomination, leading to a renewed proxy contest.
• The ongoing activist involvement by Saba Capital could create uncertainty regarding the Issuer's corporate governance and strategic direction.

Future Outlook

The conditional withdrawal of Lawrence Epstein's nomination is subject to the Issuer maintaining its current board structure (no more than nine seats up for election) and not taking actions that disadvantage Saba's other nominees. If these conditions are met, the Nominee Agreement will terminate.

Industry Context

StockSavvy.ai notes that activist investor filings like this Schedule 13D/A are common in the closed-end fund space, where investors often seek to influence governance or unlock shareholder value through board representation or other strategic changes. Saba Capital is a prominent activist in this sector.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential reduction in proxy fight uncertainty if conditions for nominee withdrawal are met, but ongoing activist involvement could still influence future strategic decisions.
• Board of Directors: Reduced immediate pressure from a specific nominee, but the conditions imposed by Saba Capital mean the board's actions regarding its structure and other nominations will be scrutinized.

Next Steps

• The Issuer's 2026 annual meeting of shareholders will proceed, with the potential for other Saba nominees to be considered if the conditions for Epstein's withdrawal are not met or if Saba has other nominees.
• If conditions are met, the Nominee Agreement between Mr. Epstein and Saba Capital will terminate.

Key Dates

Recommendation

The conditional withdrawal of a nominee by a significant activist investor like Saba Capital introduces a nuanced situation. While it might temporarily ease proxy fight concerns for the BlackRock ESG Capital Allocation Term Trust, the conditions attached mean the activist retains leverage. Investors should hold to observe how the Issuer responds to these conditions and whether a full resolution or further contention emerges regarding board composition and governance. The selling of shares by Saba Capital, though minor, also warrants observation.

Keywords

BlackRock ESG Capital Allocation Term Trust, Saba Capital, Schedule 13D, activist investor, board nomination, proxy contest, corporate governance, common shares, beneficial ownership, Boaz Weinstein